Contemporary Amperex Technology (300750.SZ) is issuing new H shares for general authorization at a price of 628.2 Hong Kong dollars per share.
Contemporary Amperex Technology Co., Ltd. (300750.SZ) announced that the board of directors has approved the "Proposal on the Company Exercising General Authorization to Issue Shares on the Main Board of The Stock Exchange of Hong Kong Limited", agreeing for the company to issue new H shares on the Main Board of The Stock Exchange of Hong Kong Limited based on the general authorization.
Contemporary Amperex Technology (300750.SZ) announced that the Board of Directors has approved the proposal to exercise general authorization to issue new H shares on the Main Board of the Stock Exchange of Hong Kong.
On April 28, 2026 (before the trading session), the company entered into a placement agreement with the placing agent. Under this agreement, the placing agent has conditionally agreed to act as the company's placing agent, to facilitate the subscription of 62.385 million shares of placement shares by not less than six placing participants (including their ultimate beneficial owners being independent third parties) at a placing price of HK$628.20 per share.
The total proceeds from this placement amount to approximately HK$39.19 billion, with a net proceeds of approximately HK$39.11 billion. The net proceeds from the placement will be used for global new energy projects, zero carbon business expansion, research and development, supplementation of daily operational funds, and other general corporate purposes.
Related Articles

J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.






